New eye drop shows promise for Sjögren's dry eye relief

NCT ID NCT06520202

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a new eye drop called rhPRG4 in 8 people with Sjögren's syndrome-related dry eye. Participants received either the active drop or a placebo, then switched after 90 minutes. The study measured eye dryness and safety over a single day. Because the trial was very small and terminated early, results are limited.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

rhPRG4 (recombinant human proteoglycan 4) eye drops

What this could lead to

If it works, this could point toward a new eye drop to temporarily relieve dryness and discomfort in people with Sjögren's syndrome.

What could go wrong

This is a very small, early-phase study (only 8 people) that was terminated, so results may be limited. The treatment only provides short-term relief and is not a cure.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME WITH DRY EYE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Sydney Eye Hospital

    Sydney, Australia